New immunotherapy combination improves outcomes for medulloblastoma in mice

Written by Alice Bough (Future Science Group)

A team of researchers from Sanford Burnham Prebys Medical Discovery Institute (CA, USA) have reported that the combined administration of immune checkpoint inhibitors and tumor necrosis factor (TNF) can eradicate tumors in a mouse model of medulloblastoma. The authors of the study, published in Nature Neuroscience, hope that the success of their combinatorial immunotherapy approach can be replicated in pediatric clinical trials. The study involved two mouse models with medulloblastoma, one with mutations in the p53 gene and one without. Gene expression experiments allowed them to identify that tumor cells not expressing p53 did not express MHC-I proteins. Expression of...

To view this content, please register now for access

It's completely free